Company: TAK
Filing Date: 2025-12-08
Form Type: 6-K
Source: 0001395064-25-000164
Chunk: 10

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-12-08
Form: 6-K
Chunk 10
---
 2577 cdavis@lifesciadvisors.com

#### Protagonist Media Contact
Virginia Amann, Founder/CEO

ENTENTE Network of Companies

+1 833 500 0061 ext 1

virginiaamann@ententeinc.com

Takeda Media Contacts:

#### Japanese Media
Tsuyoshi Tada

tsuyoshi.tada@takeda.com

#### U.S. and International Media
Emy Gruppo emy.gruppo@takeda.com

_____________________________________________________

1. Kuykendall A, et al. Rusfertide or Placebo Plus Current Standard of Care Therapy for Polycythemia Vera: Durability of Response and Safety Results Through Week 52 From the Randomized Controlled Phase 3 VERIFY Study. Oral presentation at: American Society of Hematology Annual Meeting, December 6, 2025. Orlando, FL. Presentation ID 81.

2. Kuykendall A, et al. Rusfertide or Placebo Plus Current Standard of Care Therapy for Polycythemia Vera: Durability of Response and Safety Results Through Week 52 From the Randomized Controlled Phase 3 VERIFY Study. Abstract accepted for oral presentation at: American Society of Hematology 2025 Annual Meeting. Orlando, FL. Abstract ID 81

3. Pemmaraju N, et al. Long-term rusfertide treatment in polycythemia vera: Initial results from the Phase 2 THRIVE extension study. Abstract accepted for poster presentation at: American Society of Hematology 2025 Annual Meeting. Orlando, FL. Abstract ID 3810.